Akebia Therapeutics is a biopharmaceutical company. Co.'s portfolio includes a late-stage product candidate and a commercial product: Vadadustat, which is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to mimic the physiologic effect of altitude on oxygen availability; and Auryxia® (ferric citrate), which is approved and marketed in the U.S. for two indications which are the control of serum phosphorus levels in adult patients with chronic kidney disease (CKD) on dialysis or the Hyperphosphatemia Indication, and the treatment of iron deficiency anemia (IDA) in adult patients with CKD not on dialysis or the IDA Indication.
|
Free AKBA Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (3.50 out of 4) 60th percentile
(ranked higher than approx. 60% of all stocks covered)
Analysts' Target Price: AKBA Stock Forecast Based on Zacks ABR data; powered by Xignite |